Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?
- Authors: Fanale D.; Corsini L.R.; Pedone E.; Randazzo U.; Fiorino A.; Di Piazza M.; Brando C.; Magrin L.; Contino S.; Piraino P.; Bazan Russo T.D.; Cipolla C.; Russo A.; Bazan V.
- Publication year: 2023
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/619072
Abstract
Germline BRCA1/2 alterations in the Homologous Recombination (HR) pathway are considered as main susceptibility biomarkers to Hereditary Breast and Ovarian Cancers (HBOC). The modern molecular biology technologies allowed to characterize germline and somatic BRCA1/2 alterations in several malignancies, broadening the landscape of BRCA1/2-alterated tumors. In the last years, BRCA genetic testing, beyond the preventive value, also assumed a predictive and prognostic significance for patient management. The approval of molecules with agnostic indication is leading to a new clinical model, defined "mutational". Among these drugs, the Poly (ADP)-Ribose Polymerase inhibitors (PARPi) for BRCA1/2-deficient tumors were widely studied leading to increasing therapeutic implications. In this Review we provided an overview of the main clinical studies describing the association between BRCA-mutated tumors and PARPi response, focusing on the controversial evidence about the potential agnostic indication based on BRCA1/2 alterations in several solid tumors.